Effects of rhEPO-Fc on chronic renal anemia in Chinese patients undergoing maintenance hemodialysis - a multicenter, randomized, open-label, and phase 3 study

Sep 30, 2026

Upload by Bulrr

A multicenter, randomized, open-label, phase 3 clinical study evaluates the effects of rhEPO-Fc on chronic renal anemia in Chinese patients receiving maintenance hemodialysis. The article presents the study framework and outcomes associated with rhEPO-Fc treatment, involving participating nephrology departments across multiple hospitals in China. Publication metadata includes DOI access, author and institutional affiliations, and open-access licensing details for non-commercial use with proper citation.

LanguageEnglish

CategoryResearch & Report

FormatPDF

Pages12

Reading Time30 min

AccessFree to download

Clinical Study Title

Study Design and Context

Renal FailuRe 2025, VOl. 47, nO. 1, 2597648 [https://doi.org/10.1080/0886022X.2025.2597648](https://doi.org/10.1080/0886022X.2025.2597648) CliniCal Study Effects of rhEPO-Fc on chronic renal anemia in Chinese patients undergoing maintenance hemodialysis: a multicenter, randomized, open-label, and phase 3 study liangying Gana , Xinlu Gaob, Jingchun yaob, Xinrong Xiongc, Qingfeng Pengd, Gang longe, Fei Xiongf, yiming lig, Qingping Chenh, yuan Qini, Qingdong Xuj , Wenli Chenk, Jinsheng Xul, Huixiao Zhengm, lin yangn, Xiangming yio, ning Caop, yulan Shenq, Bing liur, Qiang Zhus, Pengfei Zhangt, Henglan Wuu, Junhua Shiv, yinhui liw, yiwen lix, Baoxing Wangy, Wenxiu Changz , Weimin yu, Rui Wen, Cangsang liu, Hongli Jiang, Rongshan li, Jihong Ou, Xinxin Jiang, aihua Zhang, aicheng yang, yean yu, Jiaqing Peng, Ke Xu, Xiuxian Wan, yi Wang, yongjun Shi, Pei Wang, Panna liu, Xiaoran Feng, Hui Xu, Chun yang, Xiaowen li, Jianing Wang, Wenmei Zhang and li Zuoa aDepartment of nephrology, Peking university People’s Hospital, Beijing, China; bDepartment of nephrology, Jiujiang university affiliated Hospital, Jiujiang, Jiangxi, China; cDepartment of nephrology, Fengcheng People’s Hospital, Fengcheng, Jiangxi, China; dDepartment of nephrology, Zhuzhou Central Hospital, Zhuzhou, Hunan, China; eDepartment of nephrology, Tianjin People’s Hospital, Tianjin, China; fDepartment of nephrology, Wuhan Hospital of Traditional Chinese and Western Medicine, The 1st Hospital of Wuhan, Yichang, Hubei, China; gDepartment of nephrology, Huanggang Central Hospital, Huanggang, Hubei, China; hDepartment of nephrology, Pingxiang People’s Hospital, Pingxiang, Jiangxi, China; iDepartment of nephrology, Guilin People’s Hospital, Guilin, Guangxi, China; jDepartment of nephrology, Jiangmen Central Hospital, Jiangmen, Guangdong, China; kDepartment of nephrology, The Central Hospital of Wuhan, Jiangan, Hubei, China; lDepartment of nephrology, The 4th Hospital of Hebei Medical university, Shijiazhuang, Hebei, China; mDepartment of nephrology, The 2nd affiliated Hospital of Xingtai Medical College, Xingtai, Hebei, China; nDepartment of nephrology, Yichang Central People’s Hospital, Yichang, Hubei, China; oDepartment of nephrology, Yueyang People’s Hospital, Yueyang, Hunan, China; pDepartment of blood Purification, General Hospital of northern Theater Command, Shenyang, liaoning, China; qDepartment of nephrology, Beijing Miyun District Hospital, Beijing, China; rDepartment of nephrology, Hebei General Hospital, Shijiazhuang, Hebei, China; sDepartment of nephrology, Huabei Petroleum Ceneral Hospital, Renqiu, Hebei, China; tDepartment of nephrology, Heping Hospital affiliated to Changzhi Medical College, Changzhi, Shanxi, China; uDepartment of nephrology, The 1st Hospital of Jiaxing, Jiaxing, Zhejiang, China; vDepartment of nephrology, Tianjin 5th Central Hospital, Tianjin, China; wDepartment of nephrology, Jilin Province FaW General Hospital, ChangChun, Jilin, China; xDepartment of nephrology, Department of nephrology, Zhejiang Provincial People’s Hospital, Hangzhou, Zhejiang, China; yDepartment of nephrology, Hebei Medical university 3rd Hospital, Shijiazhuang, Hebei, China; zDepartment of nephrology, Tianjin 1st Central Hospital, Tianjin, China; aaDepartment of nephrology, Shanxi Bethune Hospital, Taiyuan, Shanxi, China; abDepartment of nephrology, Changsha Central Hospital, Changsha, Hunan, China; acDepartment of nephrology, The 4th Hospital of Changsha, Changsha, Hunan, China; adDepartment of blood Purification, The 1st affiliated Hospital of Xi’an Jiaotong university, Xian, Shanxi, China; aeDepartment of nephrology, Shanxi Provincial People’s Hospital, Taiyuan, Shanxi, China; afDepartment of nephrology, The 1st affiliated Hospital of university of South China, Hengyang, Hunan, China; agDepartment of nephrology, Zhejiang Hospital, Hangzhou, Zhejiang, China; ahDepartment of nephrology, Xuanwu Hospital of Capital Medical university, Beijing, China; aiDepar

FAQs

What treatment does the study investigate for chronic renal anemia?

The study investigates rhEPO-Fc for chronic renal anemia in Chinese patients undergoing maintenance hemodialysis.

What study design and phase are used in this research?

It is described as a multicenter, randomized, open-label, phase 3 study.

Where can the article and supplemental data be accessed?

The content is linked via the DOI, and the supplemental data are stated to be accessible online through the same DOI.

Sep 30, 2026

Upload by Bulrr